AtlasXomics Inc.

📍 New Haven, United States🗓 Founded 2020👥 19 employees💰 Last funded 2022
Biotechnology🌐 atlasxomics.com
Website LinkedIn
AtlasXomics, a 2020 Yale spin-out, is helping researchers understand the delicate epigenetic interplay and networks between cell types in their native environment that drives pathogenesis. We have helped over 50 investigators in oncology, aging, and neuroscience among other fields to locate and characterize driving epigenetic mechanisms in the tissue microenvironment. These mechanisms underly disease states and treatment responses. AtlasXomics combines epigenomics (spatial ATAC-seq and spatial CUT&Tag) with histology to provide insight that is often missed by bulk or single cell genomic tools. Our technology is primed for multi-omics studies in the same tissue section that uniquely positions us to identify and verify functional epigenetic mechanisms with proteome and transcriptome output. Mapping the cellular environment with an unbiased epigenome focus is needed to bring research closer to ground truth in diseased tissue to improve success rates for therapeutic interventions.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in AtlasXomics Inc.?
AtlasXomics Inc. has 1 investors on record on gritt.io, including 1 early-stage backers.
When did AtlasXomics Inc. last raise funding?
The most recent investment in AtlasXomics Inc. recorded on gritt.io was in 2022.
When was AtlasXomics Inc. founded?
AtlasXomics Inc. was founded in 2020.
What industry is AtlasXomics Inc. in?
AtlasXomics Inc. operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is AtlasXomics Inc. based?
AtlasXomics Inc. is headquartered in New Haven, United States.